FindTrial
Sign In

Questionnaire survey on use of antihistamine eye drops and eyelid cream for patients with seasonal allergic conjunctivitis in 2025

Questionnaire survey on use of antihistamine eye drops and eyelid cream for patients with seasonal allergic conjunctivitis in 2025 - Questionnaire survey on use of antihistamine eye drops and eyelid cream for patients with seasonal allergic conjunctivitis in 2025

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000057395
Enrollment
1300
Registered
2025-03-25
Start date
2025-03-24
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

seasonal allergic conjunctivitis

Interventions

None listed

Sponsors

Santen Pharmaceutical Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Subjects diagnosed with seasonal allergic conjunctivitis by an ophthalmologist and prescribed antihistamine eye drops and eyelid cream after December 2024. Subjects with seasonal allergic conjunctivitis such as eye itch after December 2024.

Exclusion criteria

Exclusion criteria: Medical professionals (doctors, pharmacists, nurses, etc.) Subjects engaged in pharmaceuticals and medical devices industry Subjects engaged in pharmaceuticals distributor Subjects engaged in information provision services, research services, and advertising Subjects with severe allergic conjunctival disease (vernal keratoconjunctivitis , atopic keratoconjunctivitis)

Design outcomes

Primary

MeasureTime frame
Adherence to dosage and usage The situation of eye itch Treatment satisfaction and reasons for it—

Countries

Japan

Contacts

Public ContactHirotsugu Kishimoto

Santen Pharmaceutical Co., Ltd. Japan Medical Affairs Group

clinical@santen.co.jp06-4802-9337

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026